Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Nigrostriatal dopaminergic denervation and levodopa therapy in animal models and in parkinsonian patients are associated with an enhanced opioid transmission in the striatum. The functional role of this increase has always been a subject of debate. In this study two groups of drug-naïve macaque monkeys with MPTP-induced parkinsonism were treated daily, during four weeks, with l-Dopa alone or l-Dopa plus naltrexone, a non-selective opioid receptor antagonist. The improvement of parkinsonism in all animals treated with l-Dopa alone was clearly displayed from the first day of treatment. By contrast, naltrexone co-treatment blocked the antiparkinsonian action of l-Dopa for 7-14 days. As soon as the therapeutical action of l-Dopa appeared in naltrexone-treated monkeys, the magnitude and duration of the antiparkinsonian response were similar in both groups. Furthermore, in animals treated with l-Dopa plus naltrexone the beginning of the therapeutical effect of l-Dopa was accompanied by the appearance of dyskinesias. In this group, the severity of dyskinesias during the third and fourth weeks of treatment was significantly higher than the group treated with l-Dopa alone. The results of the present study demonstrate that in de novo MPTP parkinsonian monkeys antagonizing the action of opioid receptors worsens the motor response to l-Dopa.
Samadi
Pershia
P
Centre de recherche en Neurosciences, CHUL Sainte-Foy, Québec, Canada.
Grégoire
Laurent
L
Hadj Tahar
Abdallah
A
Di Paolo
Thérèse
T
Rouillard
Claude
C
Bédard
Paul J
PJ
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000704:Analysis of Variance; D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001522:Behavior, Animal; D004195:Disease Models, Animal; D020820:Dyskinesias / Q000209:etiology*; D005260:Female; D007980:Levodopa / Q000627:therapeutic use*; D008252:Macaca fascicularis; D009043:Motor Activity / Q000187:drug effects; D009271:Naltrexone / Q000009:adverse effects*; D009292:Narcotic Antagonists / Q000009:adverse effects*; D010052:Ovariectomy / Q000379:methods; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D018709:Statistics, Nonparametric; D013997:Time Factors
D000978:Antiparkinson Agents; D009292:Narcotic Antagonists; D007980:Levodopa; D009271:Naltrexone; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine